XBIO (Xenetic Biosciences) Float Percentage Of Total Shares Outstanding: 96.24% (As of Jul. 13, 2026)


XBIO Xenetic Biosciences Inc XBIO
79 GF Score
Price $2.74
GF Value $4.21
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is Xenetic Biosciences Float Percentage Of Total Shares Outstanding?

Xenetic Biosciences XBIO -1.44% 79 Float Percentage Of Total Shares Outstanding is 96.24% as of Jul. 13, 2026. GuruFocus rates XBIO with a GF Score™ of 79/100 and a GF Value™ of $4.21 (Possible Value Trap). The stock has 2 warning signs investors should review.

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Xenetic Biosciences's float shares is 2.20 Mil. Xenetic Biosciences's total shares outstanding is 2.29 Mil. Xenetic Biosciences's float percentage of total shares outstanding is 96.24%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Xenetic Biosciences's Insider Ownership is 22.01%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Xenetic Biosciences's Institutional Ownership is 7.38%.

XBIO
79GF Score
Xenetic Biosciences Inc XBIO
Float Percentage Of Total Shares Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Xenetic Biosciences Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Xenetic Biosciences's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=2.20/2.29
=96.24%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Float Percentage Of Total Shares Outstanding of 96.24% mean?
Xenetic Biosciences (XBIO) has a Float Percentage Of Total Shares Outstanding of 96.24% as of Jul. 13, 2026. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Xenetic Biosciences and its competitors.
Is Xenetic Biosciences' Float Percentage Of Total Shares Outstanding too high?
Xenetic Biosciences' current Float Percentage Of Total Shares Outstanding is 96.24%. Overall, Xenetic Biosciences has a GF Score™ of 79/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Xenetic Biosciences' Float Percentage Of Total Shares Outstanding compare to ACXP and SILO?
Xenetic Biosciences' Float Percentage Of Total Shares Outstanding of 96.24% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Float Percentage Of Total Shares Outstanding for a Biotechnology company?
A good Float Percentage Of Total Shares Outstanding depends on the Biotechnology industry context. However, Float Percentage Of Total Shares Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Float Percentage Of Total Shares Outstanding mean?
A high Float Percentage Of Total Shares Outstanding can signal that a stock is expensive relative to its fundamentals. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Xenetic Biosciences and its competitors. Xenetic Biosciences's current Float Percentage Of Total Shares Outstanding is 96.24%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xenetic Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Xenetic Biosciences (XBIO) is currently considered Possible Value Trap. The stock's GF Value™ is $4.21, compared to a current price of $2.74 — trading 35% below its estimated fair value. The current Float Percentage Of Total Shares Outstanding is 96.24%. Xenetic Biosciences' overall GF Score™ is 79/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Float Percentage Of Total Shares Outstanding calculated?
Float Percentage Of Total Shares Outstanding is calculated from a company's financial statements. For Xenetic Biosciences (XBIO), the current Float Percentage Of Total Shares Outstanding is 96.24% as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Xenetic Biosciences (XBIO) Overvalued in 2026?

Based on GuruFocus' analysis, Xenetic Biosciences stock appears to be undervalued. The current stock price of $2.74 is trading 35% below its estimated GF Value™ of $4.21. GuruFocus considers Xenetic Biosciences to be Possible Value Trap.

Key valuation signals for XBIO:

  • Float Percentage Of Total Shares Outstanding: 96.24%
  • GF Value™: $4.21 vs. price of $2.74 (35% below fair value)
  • GF Score™: 79/100 with 2 warning signs

No single metric tells the full story. See the XBIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Xenetic Biosciences Business Description

Address 945 Concord Street, Framingham, MA, USA, 01701
Xenetic Biosciences Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. Additionally, Xenetic is leveraging PolyXen™, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen™ has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. Ltd. in the field of coagulation disorders and expects to earn royalty payments under this agreement.
79GF Score

Get the complete analysis for XBIO

Float Percentage Of Total Shares Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.74
Price
$4.21
GF Value